Sight Sciences Q1 revenue up 13% to $19.7M; raises FY 2026 guidance; Alcon damages $55.4M

Sight Sciences, Inc.

2026-Q1 EPS reported -$0.24 revenue$19,698,000

Q1 revenue $19.7M (+13% YoY); net loss $13.0M ($0.24 loss per share) vs $14.2M loss in prior year.
Interventional Dry Eye revenue $1.4M (+244% YoY, +87% QoQ); Glaucoma revenue $18.3M (+7% YoY).
FY 2026 revenue guidance raised to $83M-$89M from $82M-$88M; adj. opex reaffirmed $93M-$96M.
Final Alcon judgment: $55.4M past damages + 10% ongoing royalty for Hydrus patent infringement (subject to appeal).

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.